l
e
e
r
influenza
remain
signific
public
health
challeng
emerg
antigen
shift
highli
virul
strain
antivir
resist
avail
drug
adamantan
neuraminidas
inhibitor
appear
rapidli
creat
need
new
antivir
target
new
drug
influenza
viru
infect
use
forward
chemic
genet
identifi
influenza
nucleoprotein
np
druggabl
target
found
smallmolecul
compound
nucleozin
trigger
aggreg
np
inhibit
nuclear
accumul
nucleozin
imped
influenza
viru
replic
vitro
nanomolar
median
effect
concentr
ec
protect
mice
challeng
lethal
dose
avian
influenza
result
demonstr
viral
np
valid
target
develop
smallmolecul
therapi
propens
influenza
viru
develop
resist
commonli
use
drug
requir
continu
develop
new
therapeut
flu
season
almost
season
influenza
virus
circul
unit
state
resist
neuraminidas
inhibitor
oseltamivir
tamiflu
isol
virus
resist
adamantan
half
indi
vidual
infect
subtyp
die
irrespect
treatment
class
drug
previou
studi
sar
corona
viru
demonstr
forward
chemic
genet
approach
use
chemic
librari
compound
divers
structur
could
interrog
known
target
viral
infect
screen
librari
use
madindarbi
canin
kidney
mdck
cellbas
influenza
infect
assay
identifi
compound
show
protect
effect
primari
hit
evalu
select
compound
secondari
screen
use
cytopath
effect
assay
select
compound
studi
base
potenc
investig
mode
action
bioactiv
compound
focus
process
crucial
success
establish
influenza
infect
influenza
np
abundantli
express
protein
cours
infect
multipl
function
np
accumul
nucleu
earli
phase
infect
exclus
di
tribut
cytoplasm
later
viral
assembl
matur
examin
effect
compound
np
nuclear
traf
fick
fluoresc
microscopi
identifi
compound
block
nuclear
accumul
np
compound
show
best
potenc
ec
plaqu
reduct
assay
pra
mdck
cell
infect
influenza
viru
schemat
represent
procedur
result
primari
secondari
subsequ
fluoresc
microscopi
screen
sum
mariz
supplementari
figur
base
structur
inform
compound
four
struc
tural
similar
analog
fig
obtain
commerci
sourc
shown
ec
influenza
viru
sub
micromolar
level
pra
select
compound
nucleozin
character
base
better
solubl
aqueou
solut
unpublish
observ
potent
antivir
activ
nucleozin
inhibit
infect
mdck
cell
virus
influenza
clinic
isol
ec
pra
respect
fig
sever
suppress
viral
growth
total
inhibit
viru
product
multicycl
growth
assay
fig
compound
tc
toxic
concentr
demonstr
mtt
bromid
assay
suggest
wide
therapeut
window
supplementari
fig
furthermor
nucleozin
effect
inhibit
viral
growth
even
ad
within
h
inocul
mdck
cell
viru
fig
indic
antivir
activ
nucleozin
resid
postentri
postnuclear
event
suggest
multipl
process
involv
np
may
affect
although
nuclear
import
process
np
readili
observ
detail
fluoresc
microscopi
studi
use
human
alveolar
basal
epitheli
cell
host
influenza
viru
infect
show
nucleozin
potent
antagonist
np
accumul
nucleu
lead
format
halo
dens
np
surround
perinuclear
region
cytoplasm
h
infect
fig
np
fail
enter
nucleu
l
e
e
r
influenza
remain
signific
public
health
challeng
emerg
antigen
shift
highli
virul
strain
antivir
resist
avail
drug
adamantan
neuraminidas
inhibitor
appear
rapidli
creat
need
new
antivir
target
new
drug
influenza
viru
infect
use
forward
chemic
genet
identifi
influenza
nucleoprotein
np
druggabl
target
found
smallmolecul
compound
nucleozin
trigger
aggreg
np
inhibit
nuclear
accumul
nucleozin
imped
influenza
viru
replic
vitro
nanomolar
median
effect
concentr
ec
protect
mice
challeng
lethal
dose
avian
influenza
result
demonstr
viral
np
valid
target
develop
smallmolecul
therapi
propens
influenza
viru
develop
resist
commonli
use
drug
requir
continu
develop
new
therapeut
flu
season
almost
season
influenza
virus
circul
unit
state
resist
neuraminidas
inhibitor
oseltamivir
tamiflu
isol
virus
resist
adamantan
half
indi
vidual
infect
subtyp
die
irrespect
treatment
class
drug
previou
studi
sar
corona
viru
demonstr
forward
chemic
genet
approach
use
chemic
librari
compound
divers
structur
could
interrog
known
target
viral
infect
screen
librari
use
madindarbi
canin
kidney
mdck
cellbas
influenza
infect
assay
identifi
compound
show
protect
effect
primari
hit
evalu
select
compound
secondari
screen
use
cytopath
effect
assay
select
compound
studi
base
potenc
investig
mode
action
bioactiv
compound
focus
process
crucial
success
establish
influenza
infect
influenza
np
abundantli
express
protein
cours
infect
multipl
function
np
accumul
nucleu
earli
phase
infect
exclus
di
tribut
cytoplasm
later
viral
assembl
matur
examin
effect
compound
np
nuclear
traf
fick
fluoresc
microscopi
identifi
compound
block
nuclear
accumul
np
compound
show
best
potenc
ec
plaqu
reduct
assay
pra
mdck
cell
infect
influenza
viru
schemat
represent
procedur
result
primari
secondari
subsequ
fluoresc
microscopi
screen
sum
mariz
supplementari
figur
base
structur
inform
compound
four
struc
tural
similar
analog
fig
obtain
commerci
sourc
shown
ec
influenza
viru
sub
micromolar
level
pra
select
compound
nucleozin
character
base
better
solubl
aqueou
solut
unpublish
observ
potent
antivir
activ
nucleozin
inhibit
infect
mdck
cell
virus
influenza
clinic
isol
ec
pra
respect
fig
sever
suppress
viral
growth
total
inhibit
viru
product
multicycl
growth
assay
fig
compound
tc
toxic
concentr
demonstr
mtt
bromid
assay
suggest
wide
therapeut
window
supplementari
fig
furthermor
nucleozin
effect
inhibit
viral
growth
even
ad
within
h
inocul
mdck
cell
viru
fig
indic
antivir
activ
nucleozin
resid
postentri
postnuclear
event
suggest
multipl
process
involv
np
may
affect
although
nuclear
import
process
np
readili
observ
detail
fluoresc
microscopi
studi
use
human
alveolar
basal
epitheli
cell
host
influenza
viru
infect
show
nucleozin
potent
antagonist
np
accumul
nucleu
lead
format
halo
dens
np
surround
perinuclear
region
cytoplasm
h
infect
fig
np
fail
enter
nucleu
l
e
e
r
presenc
nucleozin
np
trap
cytoplasm
seen
scatter
randomli
host
cell
h
infect
fig
nucleozin
also
inhibit
nuclear
accumul
np
virusinfect
mdck
cell
supplementari
fig
suggest
mechan
action
nucleozin
restrict
particular
cell
type
use
publish
crystal
structur
influenza
np
carri
molecular
dock
studi
tri
see
np
direct
molecular
target
nucleozin
unbias
predict
virtual
dock
set
dock
potenti
gradient
box
cover
entir
np
mono
mer
probe
potenti
bind
site
identifi
three
potenti
bind
site
nucleozin
fig
previous
unidentifi
small
groov
bind
site
supplementari
fig
back
bodi
np
argininerich
groov
bind
site
supplementari
fig
propos
rna
bind
domain
propos
tail
loop
groov
bind
site
supplementari
fig
dock
method
treat
nucleoprotein
rigid
molecul
thu
might
perfectli
resembl
bind
nucleozin
nucleo
protein
vivo
dock
result
consid
preliminari
indic
potenti
bind
site
subject
val
idat
biochem
mutat
studi
local
bind
site
nucleozin
np
escap
viru
mutant
resist
nucleozin
select
increas
concentr
nucleozin
abl
obtain
escap
mutant
use
nucleozin
select
agent
escap
mutant
show
crossresist
nucleozin
obtain
five
passag
select
use
compound
resist
viral
clone
plaqu
purifi
select
studi
noteworthi
absenc
nucleozin
viral
titer
resist
mutant
slightli
lower
parent
viru
low
multipl
iti
infect
moi
condit
supplementari
fig
order
magnitud
lower
wildtyp
viru
high
moi
use
unpublish
observ
specul
escap
mutant
viru
may
produc
defect
interf
particl
high
moi
observ
may
applic
mutant
gener
strain
influenza
viru
furthermor
although
mutant
viru
seem
less
fit
infect
mdck
cell
compar
wildtyp
wsn
viru
caution
fit
laboratoryinduc
mutant
viru
could
meaning
evalu
context
relev
anim
model
sequenc
eight
gene
segment
escap
viru
reveal
singl
ttoc
mutat
nucleotid
posit
np
gene
segment
influenza
genom
mutat
translat
singl
amino
acid
substitut
tyrosin
histidin
residu
np
confirm
substitut
inde
mutat
contribut
resist
phenotyp
select
mutant
viru
use
revers
genet
creat
influenza
recombin
viru
singl
nucleotid
substitut
c
posit
np
gene
cotransfect
eight
base
plasmid
replac
mutant
plasmid
encod
gene
segment
viru
cocultur
cell
plaqu
purifi
isol
result
recombin
viru
singl
substitut
np
demonstr
recombin
viru
resist
high
concentr
nucleozin
resist
profil
indistinguish
origin
isol
resist
escap
viral
clone
fig
l
e
e
r
fluoresc
microscopi
studi
show
np
escap
mutant
accumul
nucleu
despit
presenc
nucleozin
fig
indic
mutat
overcam
observ
antagonist
effect
nucleozin
nuclear
accumul
np
support
notion
nucleozin
inhibit
viral
infect
halt
nuclear
accumul
viral
np
result
luciferas
reporterbas
minigenom
assay
show
concentr
nucleozin
effect
abolish
replic
viru
littl
effect
variant
np
fig
result
minigenom
assay
also
indic
replic
activ
lower
wildtyp
np
might
explain
lower
np
signal
immunofluor
cenc
studi
fig
use
purifi
recombin
wildtyp
np
np
nuclear
import
assay
nuclear
import
wildtyp
np
abolish
presenc
nucleozin
fig
indic
nucleozin
act
np
absenc
viral
compon
inabl
nucleozin
inhibit
variant
np
nuclear
import
show
crucial
mutat
nucleozin
resist
influenza
np
six
tryptophan
residu
scatter
protein
bind
exogen
molecul
like
induc
chang
microenviron
tryptophan
molecul
lead
chang
intrins
fluoresc
fluoresc
spectroscopi
show
incub
nucleozin
purifi
recombin
np
elicit
clear
dosedepend
fluorescencequench
effect
indic
nucleozin
bind
influenza
np
bind
may
induc
conform
chang
protein
fluoresc
titrat
use
variant
np
result
much
lower
fluorescencequench
effect
suggest
bind
nucleozin
variant
np
much
weaken
total
abolish
fig
dock
model
supplementari
fig
suggest
residu
np
form
hydrogen
bond
nucleozin
residu
form
hydrophob
interact
nucleozin
aromat
ring
stack
replac
tyrosin
histidin
posit
presum
disrupt
ring
stack
effect
destabil
bind
nucleozin
np
experiment
result
mutant
viru
agre
predict
bind
nucleozin
np
small
groov
behind
bodi
fig
supplementari
fig
np
like
critic
bind
nucleozin
sequenc
np
gene
ten
independ
nucleozinresist
clone
mutant
rais
experi
shown
nine
clone
mutant
one
clone
carri
instead
mutat
second
resist
mutat
reconcil
well
origin
predict
dock
model
fig
supplementari
fig
suggest
may
stabil
bind
nucleozin
hydrogen
bond
close
proxim
identifi
nuclear
localiza
tion
signal
residu
np
make
unlik
direct
interact
nucleozin
element
relat
nuclear
local
signal
respons
inhibitori
effect
specul
bind
nucleozin
influenza
np
may
induc
conform
chang
protein
render
np
unsuit
fig
caus
dosedepend
reduct
nprna
complex
could
run
polyacrylamid
gradient
gel
fig
c
lane
result
suggest
nucleozin
induc
format
larg
nprna
aggreg
big
get
gradient
gel
electrophoresi
np
assay
lost
account
degrad
appar
separ
reaction
content
denatur
sdspage
reduc
condit
detect
intact
np
supplementari
fig
indic
presenc
np
aggreg
could
dissolv
denatur
condit
absenc
rna
nucleozin
treat
ment
could
also
reduc
amount
np
run
nativ
gradient
gel
dosedepend
manner
judg
intensi
tie
coomassi
bluestain
np
lane
fig
lane
presum
due
format
larg
np
complex
separ
reaction
content
denatur
sdspage
demonstr
np
present
compar
level
treat
untreat
sampl
detect
denatur
condit
supplementari
fig
data
suggest
although
nucleozin
alon
induc
np
aggr
gate
format
presenc
rna
system
greatli
enhanc
format
larg
nprna
complex
nonresolv
nativ
electrophoresi
variant
np
hand
inert
addit
nucleozin
absenc
presenc
rna
fig
lane
fig
lane
investig
nucleozin
also
induc
np
aggreg
format
cell
express
np
mdck
cell
suffici
amount
np
present
immunofluoresc
microscopi
detect
treat
cell
cycloheximid
stop
protein
translat
ad
nucleozin
cell
monitor
np
aggreg
format
immunofluoresc
microscopi
format
nucleozin
induc
np
aggreg
could
detect
h
addit
nucleozin
unpublish
observ
readili
observ
h
addit
nucleozin
fig
specul
halo
dens
np
surround
perinuclear
region
infect
cell
nucleozininduc
np
aggreg
fig
base
immunofluoresc
biochem
data
pro
pose
nucleozin
inactiv
np
induc
format
larg
np
complex
aggreg
rna
possibl
cel
lular
compon
yet
identifi
lead
complet
halt
np
nuclear
import
np
involv
differ
step
crucial
viral
replic
mani
phase
replic
cycl
specul
process
involv
np
also
disrupt
nucleozinmedi
format
np
complex
respect
vivo
antivir
efficaci
mice
treat
nucleo
zin
consider
higher
surviv
rate
inocul
influenza
viru
strain
untreat
control
protect
highli
pathogen
strain
high
light
efficaci
compound
viru
rapidli
di
semin
multipl
organ
kill
host
soon
infect
without
treatment
mice
die
inocul
mice
surviv
treat
potent
neuraminidas
inhibitor
zanamivir
relenza
nucleozintr
group
receiv
two
dose
nucleozin
mgml
nucleozin
per
day
surviv
fig
three
mice
l
e
e
r
euthan
treat
untreat
group
day
infect
lung
test
presenc
live
viru
plaqu
assay
tenfold
reduct
viral
load
lung
nucleozintr
mice
compar
untreat
control
group
fig
anim
studi
result
show
nucleozin
protect
mice
hypervirul
influenza
viru
vivo
thu
potenti
develop
use
antiinfluenza
therapeut
manuscript
prepar
novel
swineorigin
influenza
soiv
viru
appear
analyz
publicli
avail
np
sequenc
human
influenza
subtyp
reveal
although
rare
polymorph
influenza
virus
newli
emerg
soiv
natur
variant
among
variant
detect
virus
belong
soiv
supplementari
tabl
soiv
high
resist
nucleozin
ec
data
shown
mdck
cell
infect
model
close
analog
compound
nucleozin
shown
promis
antivir
activ
variant
soiv
ec
respect
howev
reduc
activ
toward
wildtyp
wsn
viru
ec
supplementari
fig
molecular
model
suggest
may
bind
favo
rabli
bind
site
nucleozin
supplementari
fig
hydrogen
bond
format
np
residu
observ
origin
nucleozinnp
bind
model
supplementari
fig
abolish
presum
lead
reduc
activ
toward
wildtyp
wsn
viru
compar
nucleozin
mutat
studi
bind
site
nucleozin
deriv
conjunct
structureact
relationship
warrant
gener
use
smallmolecul
compound
target
np
varieti
viral
strain
summari
use
forward
chemic
genet
approach
identifi
influenza
np
druggabl
target
also
describ
lead
compound
nucleozin
efficaci
vitro
anim
studi
nucleozin
induc
format
np
aggreg
antagon
nuclear
accumul
lead
cessat
viral
replic
investig
nucleoprotein
virus
direct
druggabl
target
smallmolecul
therapeut
warrant
method
associ
refer
avail
onlin
version
paper
http
wwwnaturecomnaturebiotechnolog
ht
data
analysi
ht
data
transfer
dell
precis
workstat
normal
custom
design
data
analysi
softwar
two
stage
stage
one
normal
well
divid
median
plate
normal
valu
obtain
well
ht
carri
triplic
second
stage
normal
took
account
variat
well
final
read
calcul
aver
age
two
closest
read
twostag
normal
method
mini
mize
potenti
experiment
error
usual
random
sporad
natur
secondari
screen
secondari
screen
carri
triplic
tissu
cultur
plate
tpp
select
compound
first
dispens
well
follow
addit
mdck
cell
pfu
influenza
viru
well
plate
incub
co
monitor
daili
use
leica
dm
invert
light
microscop
virusinduc
cytopath
effect
compound
gave
full
protect
mdck
cell
cytopath
effect
select
studi
cytotox
select
compound
determin
mtt
assay
accord
manufactur
instruct
plaqu
reduct
assay
pra
assay
perform
triplic
tissu
cultur
plate
tpp
mdck
cell
seed
cellswel
emem
invitrogen
fb
day
carri
assay
h
pfu
influenza
viru
ad
cell
monolay
without
addit
compound
plate
incub
h
co
remov
unbound
viral
particl
aspir
cell
monolay
wash
emem
overlaid
low
melt
agaros
cambrex
emem
contain
fb
tpck
trypsin
invitrogen
appropri
amount
compound
plate
incub
co
h
h
infec
tion
well
fix
formaldehyd
bdh
remov
agaros
plug
monolay
stain
crystal
violet
bdh
plaqu
count
percentag
plaqu
inhibit
rel
control
without
addit
compound
plate
determin
compound
concentr
ec
calcul
use
sigma
plot
spss
pra
carri
triplic
repeat
twice
confirm
multicycl
growth
experi
evalu
antivir
activ
compound
moi
use
accordingli
viral
yield
determin
plaqu
assay
immunofluoresc
microscopi
mdck
cell
grown
confluenc
coverslip
cell
infect
h
moi
moi
mdck
cell
respect
presenc
absenc
nucleozin
wash
nucleozin
maintain
cultur
throughout
experi
infect
stop
indic
time
point
fixat
paraformaldehyd
electron
microscopi
scienc
min
cell
permeabil
min
incub
h
primari
antibodi
np
abcam
pb
contain
goat
serum
dilut
wash
stain
fluo
rescein
isothiocyan
fitc
conjug
secondari
antibodi
invitrogen
dilut
h
coverslip
wash
counterstain
dihydrochlorid
dapi
invitrogen
nucleu
local
mount
slide
use
prolong
gold
antifad
mount
medium
invitrogen
imag
analysi
fluoresc
micro
scopi
spot
diagnost
instrument
full
influenza
np
np
gene
clone
vector
novagen
ctermin
histag
pro
vide
vector
express
escherichia
coli
cell
recombin
np
purifi
homogen
histrap
hp
hitrap
heparin
hp
superdex
gel
filtrat
column
amersham
bioscienc
purifi
protein
pure
determin
sdspage
fluoresc
spectroscopi
fluorescencequench
method
use
examin
nucleozin
interact
purifi
influenza
np
vitro
briefli
hitachi
fluoresc
spectrophotomet
use
fluoresc
titrat
ml
quartz
cuvett
excit
emiss
wavelength
set
nm
nm
respect
sampl
con
tain
purifi
influenza
np
mm
tri
mm
nacl
ph
nucleozin
use
concentr
titrat
addit
allow
exceed
total
volum
solut
experi
carri
duplic
repeat
three
time
confirm
postul
potenti
bind
site
nucleozin
viral
np
molecular
model
npnucleozin
interact
perform
use
ref
charmm
forc
field
amino
acid
residu
defin
tertiari
structur
avail
np
crystal
structur
viru
protein
data
bank
code
swissmodel
use
repair
structur
np
threedimension
structur
nucleozin
gener
cambridgesoft
hydrogen
atom
assign
sybyl
file
autodock
prepar
insightii
accelri
partial
charg
potenti
assign
charmm
forc
field
lamarckian
genet
algorithm
default
paramet
use
dock
carri
dock
model
complex
nucleozin
interact
influenza
np
obtain
charmm
forc
field
use
optim
dock
complex
remov
bad
contact
ligand
protein
pymol
delano
use
plot
model
figur
one
method
mutant
gener
follow
rais
mutant
virus
resist
compound
nucleozin
briefli
influenza
passag
mdck
cell
presenc
increas
concentr
compound
desir
resist
viral
clone
purifi
plaqu
isola
tion
mdck
cell
monolay
took
five
passag
obtain
escap
mutant
plaqu
purif
carri
whole
genom
sequenc
one
clone
escap
mutant
viral
rna
extract
trizol
reagent
invitrogen
complementari
dna
cdna
eight
segment
obtain
revers
transcript
use
superscript
iii
revers
transcriptas
invitrogen
cdna
amplifi
pcr
accord
standard
procedur
